BRPI0511765A - métodos de tratar cáncer de mama, de pulmão, e colo-retal em um mamìfero - Google Patents
métodos de tratar cáncer de mama, de pulmão, e colo-retal em um mamìferoInfo
- Publication number
- BRPI0511765A BRPI0511765A BRPI0511765-8A BRPI0511765A BRPI0511765A BR PI0511765 A BRPI0511765 A BR PI0511765A BR PI0511765 A BRPI0511765 A BR PI0511765A BR PI0511765 A BRPI0511765 A BR PI0511765A
- Authority
- BR
- Brazil
- Prior art keywords
- mammal
- lung
- methods
- colorectal cancer
- treating breast
- Prior art date
Links
- 241000124008 Mammalia Species 0.000 title abstract 3
- 206010006187 Breast cancer Diseases 0.000 title abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 2
- 206010009944 Colon cancer Diseases 0.000 title abstract 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 title abstract 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 title abstract 2
- 210000000481 breast Anatomy 0.000 title abstract 2
- 210000004072 lung Anatomy 0.000 title abstract 2
- 201000005202 lung cancer Diseases 0.000 title abstract 2
- 208000020816 lung neoplasm Diseases 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 abstract 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 abstract 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 abstract 1
- DRYRBWIFRVMRPV-UHFFFAOYSA-N quinazolin-4-amine Chemical class C1=CC=C2C(N)=NC=NC2=C1 DRYRBWIFRVMRPV-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
MéTODOS DE TRATAR CáNCER DE MAMA, DE PULMãO, E COLO-RETAL EM UM MAMìFERO A presente invenção refere-se a um método de tratamento de câncer em um mamífero pela administração de 4-quinazolinaminas e pelo menos um composto antineoplásico adicional. Em particular, o método refere-se a um método de tratamento de cânceres pela administração de N-{3-cloro-4-¢(3-fluoro-benzil)-óxi!-fenil}-6-¢5-({¢2-(metano-sulfonil)-etil! -amino}-metil)-2-furil!-4-quinazolinamina e de seus sais e solvatos em combinação com pelo menos um composto antineoplásico adicional.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57733704P | 2004-06-04 | 2004-06-04 | |
| PCT/US2005/019568 WO2005120512A2 (en) | 2004-06-04 | 2005-06-03 | Cancer treatment method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0511765A true BRPI0511765A (pt) | 2008-01-08 |
Family
ID=35503649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0511765-8A BRPI0511765A (pt) | 2004-06-04 | 2005-06-03 | métodos de tratar cáncer de mama, de pulmão, e colo-retal em um mamìfero |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20090317383A1 (pt) |
| EP (1) | EP1765344A4 (pt) |
| JP (1) | JP2008501708A (pt) |
| KR (1) | KR20070034536A (pt) |
| CN (2) | CN101564535A (pt) |
| AU (2) | AU2005251769B2 (pt) |
| BR (1) | BRPI0511765A (pt) |
| CA (1) | CA2569139A1 (pt) |
| IL (1) | IL179323A0 (pt) |
| MA (1) | MA28901B1 (pt) |
| MX (1) | MXPA06013952A (pt) |
| NO (1) | NO20066079L (pt) |
| RU (2) | RU2361589C2 (pt) |
| WO (1) | WO2005120512A2 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006066267A2 (en) * | 2004-12-17 | 2006-06-22 | Smithkline Beecham (Cork) Limited | Cancer treatment method |
| WO2007143483A2 (en) * | 2006-06-01 | 2007-12-13 | Smithkline Beecham Corporation | Combination of pazopanib and lapatinib for treating cancer |
| JP2010501572A (ja) * | 2006-08-22 | 2010-01-21 | コンサート ファーマシューティカルズ インコーポレイテッド | ４−アミノキナゾリン誘導体およびその使用方法 |
| EA200970353A1 (ru) | 2006-10-06 | 2009-10-30 | Такеда Фармасьютикал Компани Лимитед | Комбинированное лекарственное средство |
| WO2008067144A2 (en) * | 2006-11-28 | 2008-06-05 | Smithkline Beecham (Cork) Limited | Cancer treatment method |
| AU2008205457A1 (en) * | 2007-01-18 | 2008-07-24 | University Of Southern California | Gene polymorphisms predictive for dual TKI therapy |
| EP2255830A1 (en) | 2008-03-03 | 2010-12-01 | Takeda Pharmaceutical Company Limited | Concomitant drug |
| WO2009137714A2 (en) | 2008-05-07 | 2009-11-12 | Teva Pharmaceutical Industries Ltd. | Forms of lapatinib ditosylate and processes for preparation thereof |
| EP2393488B1 (en) | 2009-02-06 | 2019-06-19 | University Of Southern California | Therapeutic compositions comprising monoterpenes |
| US8568968B2 (en) | 2009-04-13 | 2013-10-29 | University Of Southern California | EGFR polymorphisms predict gender-related treatment |
| US20140302050A1 (en) * | 2011-11-09 | 2014-10-09 | Albert Einstein College Of Medicine Of Yeshiva University | Targeting an amphiregulin-derived cell surface neo-epitope |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5786344A (en) * | 1994-07-05 | 1998-07-28 | Arch Development Corporation | Camptothecin drug combinations and methods with reduced side effects |
| CN1261275A (zh) * | 1997-05-27 | 2000-07-26 | 巴克·诺顿药物有限公司 | 给予病人口服紫杉烷类药物的方法和组合物 |
| RS49779B (sr) * | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| CA2401191C (en) * | 2000-02-28 | 2006-05-02 | Aventis Pharma S.A. | A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer |
| AU2001273071B2 (en) * | 2000-06-30 | 2005-09-08 | Glaxo Group Limited | Quinazoline ditosylate salt compounds |
| DE60203260T2 (de) * | 2001-01-16 | 2006-02-02 | Glaxo Group Ltd., Greenford | Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs |
| PA8578001A1 (es) * | 2002-08-07 | 2004-05-07 | Warner Lambert Co | Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas |
| EP1653986A4 (en) * | 2003-08-01 | 2007-03-14 | Smithkline Beecham Corp | TREATMENT OF P95 ERBB2 EXPRESSIVE CARCINOMA |
| US8211030B2 (en) * | 2009-03-26 | 2012-07-03 | The General Electric Company | NIBP target inflation pressure automation using derived SPO2 signals |
-
2005
- 2005-06-03 CA CA002569139A patent/CA2569139A1/en not_active Abandoned
- 2005-06-03 AU AU2005251769A patent/AU2005251769B2/en not_active Expired
- 2005-06-03 EP EP05758577A patent/EP1765344A4/en not_active Withdrawn
- 2005-06-03 BR BRPI0511765-8A patent/BRPI0511765A/pt not_active IP Right Cessation
- 2005-06-03 CN CNA2009101415491A patent/CN101564535A/zh active Pending
- 2005-06-03 RU RU2006142418/14A patent/RU2361589C2/ru not_active IP Right Cessation
- 2005-06-03 CN CN200580018262XA patent/CN1984656B/zh not_active Expired - Lifetime
- 2005-06-03 MX MXPA06013952A patent/MXPA06013952A/es active IP Right Grant
- 2005-06-03 US US11/569,878 patent/US20090317383A1/en not_active Abandoned
- 2005-06-03 WO PCT/US2005/019568 patent/WO2005120512A2/en not_active Ceased
- 2005-06-03 JP JP2007515618A patent/JP2008501708A/ja active Pending
- 2005-06-03 KR KR1020067027698A patent/KR20070034536A/ko not_active Ceased
-
2006
- 2006-11-16 IL IL179323A patent/IL179323A0/en unknown
- 2006-12-25 MA MA29554A patent/MA28901B1/fr unknown
- 2006-12-29 NO NO20066079A patent/NO20066079L/no not_active Application Discontinuation
-
2008
- 2008-10-09 AU AU2008229859A patent/AU2008229859A1/en not_active Abandoned
- 2008-12-19 RU RU2008150250/14A patent/RU2008150250A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2361589C2 (ru) | 2009-07-20 |
| WO2005120512A2 (en) | 2005-12-22 |
| MA28901B1 (fr) | 2007-10-01 |
| CA2569139A1 (en) | 2005-12-22 |
| CN1984656B (zh) | 2010-05-26 |
| NO20066079L (no) | 2007-01-12 |
| CN101564535A (zh) | 2009-10-28 |
| EP1765344A4 (en) | 2009-12-02 |
| US20090317383A1 (en) | 2009-12-24 |
| IL179323A0 (en) | 2007-05-15 |
| CN1984656A (zh) | 2007-06-20 |
| AU2005251769A1 (en) | 2005-12-22 |
| EP1765344A2 (en) | 2007-03-28 |
| AU2008229859A1 (en) | 2008-10-30 |
| MXPA06013952A (es) | 2007-02-08 |
| AU2005251769B2 (en) | 2008-10-02 |
| RU2006142418A (ru) | 2008-07-20 |
| KR20070034536A (ko) | 2007-03-28 |
| RU2008150250A (ru) | 2010-06-27 |
| JP2008501708A (ja) | 2008-01-24 |
| WO2005120512A3 (en) | 2006-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125027T1 (el) | Μονοκλωνικα αντισωματα κατα κλαουδινης-18 για τη θεραπεια του καρκινου | |
| BRPI0511765A (pt) | métodos de tratar cáncer de mama, de pulmão, e colo-retal em um mamìfero | |
| CY1115571T1 (el) | Νεες ενωσεις και μεθοδοι για θεραπεια | |
| BR112022003165A2 (pt) | Método de tratamento de cânceres associados a kras | |
| CY1119956T1 (el) | Μονοκλωνικα anti-gt468 αντισωματα για θεραπεια καρκiνου | |
| PL2097453T3 (pl) | Przeciwciała monoklonalne przeciw ludzkiemu receptorowi hormonu anty-Mullerowskiego typu II (AMHR-II) | |
| EA200801428A1 (ru) | Производные пиридиазинона для лечения опухолей | |
| NO2017019I2 (no) | Enzalutamid eller et farmasøytisk akseptabelt salt derav | |
| CY1115176T1 (el) | Ρυθμιστες υποδοχεων τυπου toll | |
| CL2007000797A1 (es) | Composicion farmaceutica que comprende entre alrededor de 1 y 150 mg/ml de humab igf-1r, entre alrededor de 0,001 y 1% de al menos un humectante, entre alredededor de 1 y 100 mm de un tapon a un ph entre alrededor de 5 y 7; y uso para el tratamiento de cancer de mama, cancer de pulmon y de prostata | |
| EA200900767A1 (ru) | Антагонистические антитела против ephb3 | |
| DK1644336T3 (da) | Nitrogenholdige heteroarylforbindelser og deres anvendelse til forøgelse af endogent erythropoietin | |
| TR201900306T4 (tr) | Mek inhibitörlerini kullanma yöntemleri. | |
| EA200970737A1 (ru) | Оксабициклогептаны и оксабициклогептены, их получение и применение | |
| BR112016015848A2 (pt) | Composto, combinação de um composto, e, composição farmacêutica | |
| CY1112570T1 (el) | Θεραπεια καρκινων με μετασταση | |
| DK2211180T3 (da) | Anvendelse af protein SATB2 som markør til at skelne colorectal cancer fra andre former for cancer | |
| MX390949B (es) | Fragmentos de anticuerpos radiomarcados para uso en tratamiento de cancer. | |
| NO20084795L (no) | Fremgangsmate for a behandle, diagnostisere eller detektere kreft | |
| EA200970884A1 (ru) | Способы лечения рака путем введения комбинаций человеческого интерлейкина ил-18 | |
| WO2008067144A3 (en) | Cancer treatment method | |
| ATE549313T1 (de) | Verbindungen mit antitumorwirkung | |
| DE602006020611D1 (de) | Krebsbehandlungsverfahren | |
| TR200902344T1 (tr) | Anti-epidermal büyüme faktörü reseptör antikorları ile terapinin etkisinin geliştirilmesi için terapötik bileşimler. | |
| ES1056692Y (es) | Garra para marcos de puertas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: LEO OSPREY LIMITED (GB) |
|
| B25A | Requested transfer of rights approved |
Owner name: NOVARTIS AG (CH) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 14A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2517 DE 02-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |